Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received final U.S. Food and Drug Administration approval for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP in two strengths.
The product is a generic equivalent of Ascor Injection and has been designated a Competitive Generic Therapy by the U.S. FDA, according to a Friday filing on Indian bourses. It is used for the short-term treatment of scurvy in patients aged 5 months and older who cannot take vitamin C orally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.